GenixPharmaceucticals Corporation (V:GENX) — Market Cap & Net Worth
Market Cap & Net Worth: GenixPharmaceucticals Corporation (GENX)
GenixPharmaceucticals Corporation (V:GENX) has a market capitalization of $664.33K (CA$918.36K) as of July 22, 2026. Listed on the V stock exchange, this Canada-based company holds position #30800 globally and #1626 in its home market, demonstrating a -25.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenixPharmaceucticals Corporation's stock price CA$0.02 by its total outstanding shares 61224131 (61.22 Million). Review GENX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
GenixPharmaceucticals Corporation Market Cap History: 2015 to 2026
GenixPharmaceucticals Corporation's market capitalization history from 2015 to 2026. Data shows change from $2.21 Million to $664.33K (-8.77% CAGR).
GenixPharmaceucticals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenixPharmaceucticals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
601.30x
GenixPharmaceucticals Corporation's market cap is 601.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.55 Million | $924.70K | -$129.05K | 1.68x | N/A |
| 2017 | $4.43 Million | $1.01 Million | -$243.21K | 4.38x | N/A |
| 2018 | $2.44 Million | $419.96K | $134.07K | 5.80x | 18.17x |
| 2019 | $3.10 Million | $137.40K | -$164.70K | 22.56x | N/A |
| 2023 | $885.77K | $12.35K | -$4.40 Million | 71.74x | N/A |
| 2024 | $2.44 Million | $4.05K | -$73.20K | 601.30x | N/A |
Competitor Companies of GENX by Market Capitalization
Companies near GenixPharmaceucticals Corporation in the global market cap rankings as of July 22, 2026.
Key companies related to GenixPharmaceucticals Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #515 globally with a market cap of $51.87 Billion USD ( CN¥354.48 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #548 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #617 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #515 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.87 Billion | CN¥55.57 |
| #548 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.46 |
| #617 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
GenixPharmaceucticals Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, GenixPharmaceucticals Corporation's market cap moved from $2.21 Million to $ 664.33K, with a yearly change of -8.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$664.33K | -50.00% |
| 2025 | CA$1.33 Million | -45.45% |
| 2024 | CA$2.44 Million | +175.00% |
| 2023 | CA$885.77K | -73.33% |
| 2022 | CA$3.32 Million | -34.78% |
| 2021 | CA$5.09 Million | -32.35% |
| 2020 | CA$7.53 Million | +142.86% |
| 2019 | CA$3.10 Million | +27.27% |
| 2018 | CA$2.44 Million | -45.00% |
| 2017 | CA$4.43 Million | +185.71% |
| 2016 | CA$1.55 Million | -30.00% |
| 2015 | CA$2.21 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of GenixPharmaceucticals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $664.33K USD |
| MoneyControl | $664.33K USD |
| MarketWatch | $664.33K USD |
| marketcap.company | $664.33K USD |
| Reuters | $664.33K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more